Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) Stock Gains Momentum: Is it Sustainable?
Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) jumped 4% no news. The company offered its corporate updates and financial results for Q2 2021. At the end of the quarter, the company had cash and equivalents of $33.1 million, which is adequate to support completing its clinical studies for its flagship treatment candidate Seclidemstat. CEO David Arthur said that the second quarter was a considerable development period for the company, shown by the significant…